Encorafenib Combo Earns Chinese Approval in BRAF V600E+ Metastatic CRC
The big picture: In a significant move, Encorafenib combination has received approval in China for treating BRAF V600E+ Metastatic CRC.
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers
A clinical trial involving Lorigerlimab has been temporarily halted by the FDA following several serious safety events, including one treatment-related fatality.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma
There has been progressive advancement in managing immune-checkpoint inhibitor toxicities for melanoma treatment.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
The FDA has granted Fast Track status to SRN-101 for the treatment of recurrent high-grade glioma, adding to its credibility and likely its progression towards approval.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma
A newly discovered small molecule demonstrates early activity in the treatment of pretreated multiple myeloma, sparking fresh hope for patients.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC
In Brief: A study comparing the quality of life outcomes using protons and photons in OPSCC reveals important insights for treatment strategies.
